StockNews.com Begins Coverage on VBI Vaccines (NASDAQ:VBIV)

StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research note published on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Performance

VBI Vaccines stock opened at $0.63 on Thursday. VBI Vaccines has a 52-week low of $0.45 and a 52-week high of $3.53. The firm has a 50 day moving average price of $0.61 and a two-hundred day moving average price of $0.61.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Engineers Gate Manager LP bought a new position in VBI Vaccines during the 1st quarter worth approximately $26,000. Alliancebernstein L.P. raised its holdings in VBI Vaccines by 9.9% during the 3rd quarter. Alliancebernstein L.P. now owns 188,900 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 17,000 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its position in shares of VBI Vaccines by 8.8% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 267,148 shares of the biopharmaceutical company’s stock worth $443,000 after buying an additional 21,587 shares during the period. Voya Investment Management LLC grew its position in shares of VBI Vaccines by 29.7% during the 4th quarter. Voya Investment Management LLC now owns 95,428 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 21,824 shares during the period. Finally, Oppenheimer & Co. Inc. grew its position in shares of VBI Vaccines by 38.5% during the 1st quarter. Oppenheimer & Co. Inc. now owns 100,400 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 27,900 shares during the period. Institutional investors own 12.26% of the company’s stock.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.